Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer

• DOI: 10.1038/srep07162
• Publication Date: 2014-11-24T10:19:39Z
• Authors: Eun-Sun Choi; Jeong-Seok Nam; Ji-Youn Jung; Nam-Pyo Cho; Sung-Dae Cho
• Keywords: Protein Degradation; Therapeutic effect

Cervical cancer is the third most common and leading cause of death among women. However, standard treatment for cervical includes cisplatin, which can side effects such as hematological damage or renal toxicity. New innovations in focus on developing more effective better-tolerated therapies Sp1-targeting drugs. Previous studies suggested that mithramycin A (Mith) inhibits growth various cancers by decreasing Sp1 protein. how protein decreased Mith not clear. Few have investigated regulation proteasome-dependent degradation a possible control mechanism cells. Here, we show inducing degradation, thereby suppressing through DR5/caspase-8/Bid signaling pathway. We found prolonged was well tolerated after systemic administration to mice carrying Reduction body weight minimal, indicating good therapeutic candidate involved promoting disease.